Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer.
Författare
Summary, in English
Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial and time-limited response to therapy before the cancer progresses and the patient succumbs to the disease. Despite recent advances in early diagnosis and treatment, approximately one-third of treated patients will relapse and become resistant to currently available treatments. In this review we evaluate current treatment practices and recent advances in therapy for localized prostate malignancy and advanced, metastatic prostate cancer. Some of the promising new drugs for PCa treatment include MDV3100, an androgen receptor (AR) antagonist that prevents androgens from binding to the AR and nuclear translocation and co-activator recruitment of the ligand-receptor complex; abiraterone, an orally administered drug that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17; and several newer cytotoxic drugs (epothilones, satraplatin). Key new insights are that cancer stem cells play a role in PCa and that PCa cells are dependent on the AR for proliferation, even in the hormone refractory state of the disease. We also discuss potential molecular targets for new drug candidates for the treatment of metastatic PCa.
Avdelning/ar
- Experimentell cancerforskning, Malmö
- Neuroendokrin cellbiologi
- Urological research, Malmö
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
Publiceringsår
2011
Språk
Engelska
Sidor
4440-4453
Publikation/Tidskrift/Serie
Current Medicinal Chemistry
Volym
18
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
Bentham Science Publishers
Ämne
- Medicinal Chemistry
Status
Published
Forskningsgrupp
- Experimental Cancer Research, Malmö
- Neuroendocrine Cell Biology
- Urological research, Malmö
ISBN/ISSN/Övrigt
- ISSN: 0929-8673